TrialBritish journal of haematology2026

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).

Andrea Gallamini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.